LexDanaLexDanabeta
New SessionDrug SearchOfficial RankingsInsights
© LexDana · beta
LexDanaLexDanabeta
New SessionDrug SearchOfficial RankingsInsights
LexDanaLexDanabeta

Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

AllCopyright & Trade Secrets59Federal Circuit877ITC / Section 33788Patent Litigation216Patent Prosecution126Pharma & ANDA62PTAB686Supreme Court61Trademark158USPTO Policy78Unsorted257

Tagged right to appeal · clear

PTAB

Eligibility for CBM Review Is Not Appealable

SIPCO, LLC v. EMERSON ELECTRIC CO. Before O’Malley, Reyna, and Chen. Appeal from the Patent Trial and Appeal Board. Summary: The Board’s determination that a patent qualifies for CBM review is non-appealable under 35 U.S.C. § 324(e).…

November 18, 2020·PTAB·2 min read
Data: FDA Orange & Purple Books · prosecution & litigation metadata · read-only.